INVESTOR ALERT: Faruqi & Faruqi, LLP Announces Investigation of Orexigen Therapeutics and Encourages Investors Who Suffered Losses in Excess of $100,000 to Contact the Firm - OREX
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) (NASDAQ: OREX).
The investigation focuses on whether the Company and its executives violated federal securities laws by making false and misleading statements and/or failing to disclose material facts regarding its business and operations.
On March 5, 2015, Forbes published a report quoting an FDA official who stated that the Company’s recent interim study results regarding their Contrave drug are extremely unreliable.
On this news, shares of Orexigen fell $0.91 per share or over 11% from its previous closing price to close at $7.10 per share on March 6, 2015,
Request more information now by clicking here: www.faruqilaw.com/OREX. There is no cost or obligation to you.
If you invested in Orexigen stock, bonds or options between November 25, 2013 and March 5, 2015 and would like to discuss your legal rights contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Orexigen’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.